Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance, strategic partnerships, and promising product development, such as the plozasiran launch and multiple drug pipelines. Despite some uncertainties in clinical trial outcomes and regulatory claims, the overall sentiment remains positive due to solid financial health, strategic partnerships, and optimistic guidance. The market cap suggests a moderate reaction, likely resulting in a positive stock price movement of 2% to 8% over the next two weeks.
Key Financial Performance
Net Loss for Fiscal Year 2025 $2 million (compared to $599 million in fiscal year 2024), a significant improvement due to increased revenue from licensing and collaboration agreements.
Revenue for Fiscal Year 2025 $829 million (compared to prior year), driven by license and collaboration agreements with Sarepta, Sanofi, and GSK. Key contributors include $697 million from Sarepta, $130 million from Sanofi, and $2.6 million from GSK.
Operating Expenses for Fiscal Year 2025 $731 million (compared to $605 million in fiscal year 2024), a 21% increase due to higher R&D expenses ($101 million increase) and SG&A costs ($25 million increase).
Cash Flow from Operating Activities $180 million net cash provided (compared to $463 million net cash used in fiscal year 2024), a $643 million positive change driven by cash received from licensing and collaboration agreements.
Cash and Investments as of September 30, 2025 $919 million (compared to $681 million as of September 30, 2024), an increase due to licensing and collaboration agreements, partially offset by ongoing cash burn.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
FDA approval of REDEMPLO: REDEMPLO is Arrowhead's first FDA-approved siRNA medicine for familial chylomicronemia syndrome (FCS). It is self-administered at home via subcutaneous injection every 3 months. The drug reduces triglycerides by 80% and has a $60,000 annual price under the One-REDEMPLO pricing model.
Pipeline programs: Progress was made on zodasiran for homozygous familial hypercholesterolemia (HoFH) and ARO-DIMER-PA for atherosclerotic cardiovascular disease (ASCVD). Zodasiran is in Phase III trials, while ARO-DIMER-PA is awaiting Phase I/II trial clearance.
Obesity programs: ARO-INHBE and ARO-ALK7 are in Phase I/II trials targeting the activin pathway to reduce fat storage. Initial data for ARO-INHBE is expected in early 2026.
CNS program: ARO-MAPT targets tauopathies like Alzheimer's disease and uses a new delivery system for blood-brain barrier penetration. Preclinical studies show promising results.
Market expansion for REDEMPLO: The drug targets 6,500 FCS patients in the U.S. and potentially 750,000 patients with persistent chylomicronemia. The One-REDEMPLO pricing model ensures consistent pricing across indications.
Business development: Arrowhead earned $200M from Sarepta and $200M upfront from Novartis for licensing agreements. The Novartis deal includes up to $2B in milestone payments and royalties.
Financial performance: Arrowhead reported $829M in revenue for fiscal 2025, driven by licensing agreements. Operating expenses increased to $731M, primarily due to R&D and commercialization costs.
Cash position: The company has $919M in cash and investments, sufficient to fund operations into fiscal 2028.
Transition to commercial-stage: With REDEMPLO's approval, Arrowhead transitions into a commercial-stage company, focusing on sustainable innovation and rational drug pricing.
Partnership strategy: Arrowhead maintains a balanced pipeline with half of its programs wholly owned and half partnered, ensuring diversified growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company faces potential regulatory hurdles in expanding the label for REDEMPLO beyond genetic and clinical FCS. The success of ongoing Phase III studies (SHASTA-3, SHASTA-4, and SHASTA-5) is critical for supplemental NDA filings and label expansion.
Market Access and Pricing Challenges: While the One-REDEMPLO pricing model has received positive early feedback, there is a risk that payers may not fully appreciate the value of REDEMPLO, potentially impacting market access and adoption.
Supply Chain and Commercialization Risks: The company is transitioning into a commercial-stage entity with REDEMPLO as its first FDA-approved product. Ensuring a smooth supply chain and effective commercialization strategy is critical, especially given the high expectations from patients and healthcare providers.
Clinical Trial Risks: The success of ongoing and future clinical trials, including SHASTA-3, SHASTA-4, and SHASTA-5, is crucial for expanding REDEMPLO's indications and for other pipeline programs like zodasiran and ARO-DIMER-PA. Delays or failures in these trials could adversely impact the company's strategic objectives.
Financial Risks: Although the company has a strong financial position, the high R&D and SG&A expenses, particularly for late-stage clinical trials and commercialization efforts, could strain resources if revenue from REDEMPLO and other programs does not materialize as expected.
Competitive Pressures: The company operates in a highly competitive biotech space, particularly in the cardiometabolic and RNAi therapeutic areas. Competitors with similar or superior products could impact market share and revenue.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
FDA approval of REDEMPLO: REDEMPLO has been approved as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). The company plans to expand its label to include severe hypertriglyceridemia through ongoing SHASTA-3 and SHASTA-4 Phase III studies, with data expected in Q3 2026 and potential regulatory submissions by the end of 2026.
Commercial launch of REDEMPLO: The drug is priced at $60,000 annually under the One-REDEMPLO pricing model, targeting approximately 6,500 FCS patients in the U.S. Early feedback from healthcare professionals and payers has been positive. The company is targeting 5,000 healthcare professionals for engagement and has launched a patient support program, Rely On REDEMPLO.
Pipeline development for zodasiran: The YOSEMITE Phase III trial for zodasiran, targeting homozygous familial hypercholesterolemia (HoFH), is expected to complete enrollment in 2026, with study completion in 2027 and a potential NDA filing by the end of 2027. A commercial launch is anticipated in 2028.
ARO-DIMER-PA program: A Phase I/II clinical trial for ARO-DIMER-PA, targeting atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia, is planned. This program represents a significant step forward in RNAi therapeutics and preventative cardiology.
ARO-MAPT program: A Phase I/II clinical trial for ARO-MAPT, targeting tauopathies including Alzheimer’s disease, is set to begin. This program utilizes a new proprietary delivery system for CNS penetration.
Obesity programs (ARO-INHBE and ARO-ALK7): Initial data for ARO-INHBE is expected in early January 2026, with more comprehensive data by mid-2026. Early safety and target engagement data for ARO-ALK7 will also be shared in 2026.
Business development and partnerships: The company has entered into a $200 million upfront licensing agreement with Novartis for ARO-SNCA, targeting Parkinson’s disease, with potential milestone payments up to $2 billion. Additionally, a $200 million milestone payment was earned from Sarepta for ARO-DM1.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Program: No specific mention of a dividend program was made during the conference call.
Share Repurchase: The company repurchased shares from Sarepta, reducing common shares outstanding by 2.4 million from the prior quarter.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the plan to show a benefit in terms of acute pancreatitis for plozasiran?
A:SHASTA-3 and 4 trials are powered for triglyceride reduction, not specifically for pancreatitis. However, they are designed to pool data for evaluating pancreatitis reduction. SHASTA-5 is specifically designed to demonstrate a benefit in acute pancreatitis with a broader patient population. The recent design change in SHASTA-5 aims to make the population more generalizable.
Q:What details can you provide about the obesity program, specifically on inhibin E and ALK7?
A:For inhibin E, data will include biomarker, MRI, and safety data from SAD and MAD cohorts, with some follow-up data from combo cohorts. ALK7 data will focus on monotherapy safety and knockdown data. Full data sets will be available later in 2026, with initial data providing an early look.
Q:What are your estimates on AP events accrual based on patient baseline characteristics and the change in plans to broaden AP adjudication criteria?
A:The modified Atlanta criteria have been adopted, making it hard to estimate the number of events. The percentage of patients with a history of pancreatitis will be shared soon, which should indicate a good chance of having the necessary number of events.
Q:How does the ARO-MAPT program differentiate from J&J's failed anti-tau antibody, and what gives confidence in the target?
A:ARO-MAPT uses siRNA to silence tau expression by delivering it across the blood-brain barrier into neurons, unlike J&J's monoclonal antibody that targets extracellular tau. This approach prevents neurofibrillary tangles from forming, offering a key differentiation.
Q:What is the visibility on launching a CVOT study and potential milestone triggers from Sarepta programs?
A:The CVOT study for the dimer is planned to start after Phase I/II studies, with pivotal studies potentially running in parallel. The first $50 million milestone from Sarepta is expected in February 2026.
Q:What data readouts are expected in 2026?
A:Key data readouts include obesity program data in early and mid-2026, dimer data in the summer, ARO-MAPT data in the summer, SHASTA-3 and 4 readouts in Q3, and an sNDA filing by year-end. Additional updates on ARO-RAGE may come at the end of 2026.
Q:What is the status of the ARO-RAGE program?
A:The program has shown promising knockdown data but lacks biomarkers for clinical benefit. A challenge study has started, with potential data by the end of 2026. The results will guide decisions on building a pulmonary franchise or partnering.
Q:What are the applications of ARO-DIMER in CVOT and mixed hyperlipidemia?
A:ARO-DIMER aims to treat mixed hyperlipidemia by lowering both LDL and triglycerides with a single quarterly injection. This approach addresses a large unmet need in the 20 million U.S. patients with mixed hyperlipidemia.
Q:What is the FDA's stance on pancreatitis evidence for a future risk reduction claim in high-risk SHTG patients?
A:The FDA has not been approached for a specific claim. SHASTA-5 was designed more for payer requirements outside the U.S. than for regulatory purposes.
Q:What level of CSF tau knockdown would indicate clinical proof of concept for the MAPT program?
A:A CSF tau knockdown of 50-60% would be considered proof of concept, based on data from other studies showing clinical benefits at these levels.
Q:What are the expectations for the REDEMPLO launch in FCS?
A:High expectations are set for the launch due to REDEMPLO's significant and sustained triglyceride reduction, reduced pancreatitis risk, favorable safety profile, and once-every-three-month dosing.
Q:Are there any adjustments planned for SHASTA-3 and 4 studies based on core study details?
A:No adjustments are planned other than adopting the modified Atlanta criteria.
Q:What is the status of the neuromuscular franchise and DMPK knockdown data?
A:The program aims to achieve knockdown levels comparable to peer benchmarks. Dose optimization is ongoing, and milestones are tied to regulatory and commercial progress.
Q:What are the inclusion criteria for the dimer study in mixed hyperlipidemia?
A:Patients with triglycerides up to 880 and either non-HDL >100 or LDL >70 are included, targeting those with both high triglycerides and high cholesterol.
Q:Review of Unclear Management Responses
A:Management avoided providing a clear answer on the exact number of AP events expected due to the adoption of the modified Atlanta criteria. They also did not specify the FDA's requirements for a pancreatitis risk reduction claim in high-risk SHTG patients, stating that they have not approached the FDA for such a claim. Additionally, they did not provide specific dose levels for optimal biomarker activity in the neuromuscular franchise.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ARO DIMER
ARO DM
DIMER PA
DM milestone
FDA approval
FDA medicine
Head RD
III trial
Medical Officer
Novartis ARO
Officer Head
Phase II
Phase III
RD SGA
Rely
SHASTA
SNCA stage
Sanofi GSK
care professional
health care
holiday
home injection
injection month
licensing collaboration
pancreatitis patient
patient caregiver
plozasiran placebo
pricing model
retirement
self home
system
week
ARWR Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Neutral6-10
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-14
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2026 Earnings Call Transcript
Unknown5-7
The earnings call reveals a net loss compared to a prior net income, increased operating expenses, and a significant revenue decline due to the absence of last year's transaction. While there is a strong cash position and positive payer feedback, the financial performance is weak, with only modest sales of REDEMPLO. The Q&A indicates cautious optimism but lacks specific guidance, which could concern investors. Considering the market cap of $3.19 billion, these factors suggest a negative stock price movement in the next two weeks.
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2026 Earnings Call Transcript
Positive2-6
The earnings call reveals strong financial performance, with a significant increase in net income and revenue driven by collaboration agreements. Product development updates, including the commercial launch of REDEMPLO and partnerships with Novartis and Sarepta, are promising. However, management's avoidance of specific questions in the Q&A might cause slight concern. The market cap suggests moderate volatility, leading to a positive stock price movement prediction of 2% to 8% over the next two weeks.
ARWR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
